The value of five blood markers in differentiating mycosis fungoides and Sézary syndrome: a validation cohort.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
22
11
2020
received:
08
07
2020
accepted:
08
12
2020
pubmed:
15
12
2020
medline:
21
9
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Clinical and histological diagnosis of Sézary syndrome (SS) and mycosis fungoides (MF) is challenging in clinical routine. We investigated five blood markers previously described for SS (T-plastin, Twist, KIR3DL2, NKp46 and Tox) in a prospective validation cohort of patients. We included 447 patients in this study and 107 patients were followed up for prognosis. The markers were analysed by reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) on peripheral blood leucocytes and CD4 We defined cut-off values for each marker. T-plastin, Twist and KIR3DL2 had the best validity. SS may be overrepresented. The combination of T-plastin and Twist was able to differentiate between erythrodermic MF or BID and SS. The additional analysis of KIR3DL2 may be useful to predict the prognosis. We propose T-plastin, Twist and KIR3DL2 measured by RT-qPCR as new diagnostic markers for Sézary syndrome.
Sections du résumé
BACKGROUND
Clinical and histological diagnosis of Sézary syndrome (SS) and mycosis fungoides (MF) is challenging in clinical routine.
OBJECTIVES
We investigated five blood markers previously described for SS (T-plastin, Twist, KIR3DL2, NKp46 and Tox) in a prospective validation cohort of patients.
METHODS
We included 447 patients in this study and 107 patients were followed up for prognosis. The markers were analysed by reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) on peripheral blood leucocytes and CD4
RESULTS
We defined cut-off values for each marker. T-plastin, Twist and KIR3DL2 had the best validity. SS may be overrepresented. The combination of T-plastin and Twist was able to differentiate between erythrodermic MF or BID and SS. The additional analysis of KIR3DL2 may be useful to predict the prognosis.
CONCLUSIONS
We propose T-plastin, Twist and KIR3DL2 measured by RT-qPCR as new diagnostic markers for Sézary syndrome.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
405-411Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 British Association of Dermatologists.
Références
Willemze R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133:1703-14.
Olsen EA. The United States Cutaneous Lymphoma Consortium (USCLC). Clin Lymphoma Myeloma Leuk 2010; 10 (Suppl. 2):S88-S89.
Scarisbrick JJ, Quaglino P, Prince HM et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019; 181:350-7.
Roelens M, de Masson A, Ram-Wolff C et al. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker. Br J Dermatol 2020; 182:1415-22. https://doi.org/10.1111/bjd.18481.
Olsen EA, Whittaker S, Kim YH et al.; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29:2598-607. https://doi.org/10.1200/JCO.2010.32.0630.
Scarisbrick JJ, Hodak E, Bagot M et al. Blood classification and blood response criteria in mycosis fungoides and Sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer 2018; 93:47-56.
Bagot M, Moretta A, Sivori S et al. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood 2001; 97:1388-91. https://doi.org/10.1182/blood.v97.5.1388.
Kari L, Loboda A, Nebozhyn M et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197:1477-88.
van Doorn R, Dijkman R, Vermeer M et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor Twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004; 64:5578-86.
Michel L, Jean-Louis F, Begue E et al. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sezary syndrome diagnosis. Blood 2013; 121:1477-8.
Tang N, Gibson H, Germeroth T et al. T-plastin (PLS3) gene expression differentiates Sezary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. Br J Dermatol 2010; 162:463-6.
Begue E, Jean-Louis F, Bagot M et al. Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma. Blood 2012; 120:143-54.
Boonk SE, Zoutman WH, Putter H et al. Increased expression of PLS3 correlates with better outcome in Sezary syndrome. J Invest Dermatol 2017; 137:754-7.
Wong HK. STAT assays with a TWIST: differentiating Sezary syndrome from erythrodermic inflammatory dermatitis. J Invest Dermatol 2016; 136:1313-5.
Goswami M, Duvic M, Dougherty A, Ni X. Increased Twist expression in advanced stage of mycosis fungoides and Sezary syndrome. J Cutan Pathol 2012; 39:500-7.
Bensussan A, Remtoula N, Sivori S et al. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sezary syndrome patients. J Invest Dermatol 2011; 131:969-76.
Freud AG, Zhao S, Wei S et al. Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia. Am J Clin Pathol 2013; 140:853-66. https://doi.org/10.1309/AJCPWGG69MCZOWMM.
Ortonne N, Huet D, Gaudez C et al. Significance of circulating T-cell clones in Sezary syndrome. Blood 2006; 107:4030-8.
Moins-Teisserenc H, Daubord M, Clave E et al. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. J Invest Dermatol 2015; 135:247-57.
Bagot M, Porcu P, Marie-Cardine A et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol 2019; 20:1160-70.
Zhang Y, Wang Y, Yu R et al. Molecular markers of early-stage mycosis fungoides. J Invest Dermatol 2012; 132:1698-706.
Yu X, Luo Y, Liu J et al. TOX acts an oncological role in mycosis fungoides. PLoS One 2015; 10:e0117479.
Dulmage BO, Akilov O, Vu JR et al. Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget 2019; 10:3104-13.
Mokkink LB, Terwee CB, Patrick DL et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010; 63:737-45.
Lian J, Liu J, Yue Y et al. The repertoire features of T cell receptor β-chain of different age and gender groups in healthy Chinese individuals. Immunol Lett 2019; 208:44-51.
Haftcheshmeh SM, Tajbakhsh A, Kazemi M et al. The clinical importance of CD4(+) CD7(-) in human diseases. J Cell Physiol 2019; 234:1179-89.
Nieto-Fontarigo JJ, Salgado FJ, San-Jose ME et al. Expansion of different subpopulations of CD26(-/low) T cells in allergic and non-allergic asthmatics. Sci Rep 2019; 9:7556.
Hurabielle C, Michel L, Ram-Wolff C et al. Expression of Sézary biomarkers in the blood of patients with erythrodermic mycosis fungoides. J Invest Dermatol 2016; 136:317-20.
Schneider P, Plassa LF, Ratajczak P et al. NKp46-specific expression on skin-resident CD4(+) lymphocytes in mycosis fungoides and Sezary syndrome. J Invest Dermatol 2014; 134:574-8.
Boonk SE, Zoutman WH, Marie-Cardine A et al. Evaluation of immunophenotypic and molecular biomarkers for Sezary syndrome using standard operating procedures: a multicenter study of 59 patients. J Invest Dermatol 2016; 136:1364-72.
Scarisbrick JJ, Prince HM, Vermeer MH et al. Cutaneous Lymphoma International Consortium Study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 2015; 33:3766-73.
Hurabielle C, Thonnart N, Ram-Wolff C et al. Usefulness of KIR3DL2 to diagnose, follow-up, and manage the treatment of patients with Sezary syndrome. Clin Cancer Res 2017; 23:3619-27.